Acumen Pharmaceuticals, Inc. (ABOS)

NASDAQ: ABOS · IEX Real-Time Price · USD
5.62
+0.02 (0.36%)
Dec 5, 2022 3:20 PM EST - Market open
0.36%
Market Cap 229.18M
Revenue (ttm) n/a
Net Income (ttm) -38.34M
Shares Out 40.50M
EPS (ttm) 1.17
PE Ratio 4.80
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 156,117
Open 5.6
Previous Close 5.6
Day's Range 5.56 - 5.69
52-Week Range 3.02 - 10.97
Beta n/a
Analysts Buy
Price Target 16.15 (+187.4%)
Earnings Date Nov 14, 2022

About ABOS

Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for the treatment of Alzheimer's disease. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, a humanized monoclonal antibody that is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is headquartered in Charlottesville, Virginia. [Read more]

Industry Biotechnology
IPO Date Jul 1, 2021
Employees 14
Stock Exchange NASDAQ
Ticker Symbol ABOS
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 12 analysts, the average rating for ABOS stock is "Buy." The 12-month stock price forecast is 16.15, which is an increase of 187.37% from the latest price.

Price Target
$16.15
(187.37% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Acumen Pharmaceuticals Reports Third Quarter 2022 Financial Results and Business Highlights

CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel targe...

2 weeks ago - GlobeNewsWire

Acumen Pharmaceuticals to Participate in the Stifel Healthcare Conference

CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel targe...

3 weeks ago - GlobeNewsWire

Acumen Pharmaceuticals to Report Third Quarter 2022 Financial Results on Nov. 14, 2022

CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel targe...

3 weeks ago - GlobeNewsWire

Acumen's ACU193, an Anti-Amyloid Beta Oligomer Antibody, Granted FDA Fast Track Designation for Alzheimer's Disease

CHARLOTTESVILLE, Va. and CARMEL, Ind., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) today announced that ACU193, the first clinical-stage monoclonal antibody that select...

1 month ago - GlobeNewsWire

Why Is Acumen (ABOS) Stock Up 95% Today?

Source: pathdoc / Shutterstock.com Acumen Pharmaceuticals (NASDAQ: ABOS ) stock is rocketing higher on Wednesday but it's not due to any news from the company. Instead, investors have Biogen (NASDAQ: BI...

2 months ago - InvestorPlace

Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2022 and Business Highlights

CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 15, 2022 (GLOBE NEWSWIRE) --  Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel targ...

3 months ago - GlobeNewsWire

Acumen Pharmaceuticals to Report Second Quarter 2022 Financial Results on August 15, 2022

CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targe...

3 months ago - GlobeNewsWire

Acumen presents poster describing method to standardize amyloid beta oligomer assays supporting therapeutic developme...

Model designed to fill need for soluble amyloid beta oligomer reference standards in bioanalytical assays Model designed to fill need for soluble amyloid beta oligomer reference standards in bioanalytic...

4 months ago - GlobeNewsWire

Acumen Pharmaceuticals to Participate in Upcoming Investor and Scientific Conferences

CHARLOTTESVILLE, Va. and CARMEL, Ind., July 26, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targe...

4 months ago - GlobeNewsWire

Acumen Pharmaceuticals Reports Financial Results for First Quarter 2022 and Business Highlights

CHARLOTTESVILLE, Va. and CARMEL, Ind., May 16, 2022 (GLOBE NEWSWIRE) --  Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel targe...

6 months ago - GlobeNewsWire

Acumen Pharmaceuticals to Report First Quarter 2022 Financial Results on May 16, 2022

CHARLOTTESVILLE, Va. and CARMEL, Ind., May 11, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel target...

6 months ago - GlobeNewsWire

Comprehensive Analysis in Frontiers in Neuroscience Highlights Acumen Pharmaceuticals' New Approach to Treating Alzhe...

Acumen focused on developing investigational monoclonal antibody targeting amyloid beta oligomers Acumen focused on developing investigational monoclonal antibody targeting amyloid beta oligomers

7 months ago - GlobeNewsWire

Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2021 and Business Highlights

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 28, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on the development of novel targ...

8 months ago - GlobeNewsWire

Acumen Pharmaceuticals to Report Fourth Quarter and Full Year 2021 Financial Results on March 28, 2022

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 16, 2022 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targ...

8 months ago - GlobeNewsWire

Acumen Pharmaceuticals Reports Financial Results for Third Quarter 2021 and Business Highlights

CHARLOTTESVILLE, Va. and CARMEL, Ind., Nov. 15, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical stage biopharmaceutical company focused on the development of novel targe...

1 year ago - GlobeNewsWire

Acumen Pharmaceuticals Reports Financial Results for Second Quarter 2021 and Business Highlights

CHARLOTTESVILLE, Va. and CARMEL, Ind., Aug. 16, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (Acumen), a clinical stage biopharmaceutical company focused on the development of no...

1 year ago - GlobeNewsWire

5 Stocks With High Insider Cluster Buys During July

According to the Insider Cluster Buys Screen, a Premium feature of Gurus, five stocks with high number of unique insider buys during the past month include German American Bancorp Inc. ( GABC , Financia...

Other symbols: ATLOGABCPTRSSPG
1 year ago - GuruFocus

Krispy Kreme and 5 Other IPOs to Begin Trading

Acumen Pharmaceuticals, D-MARKET Electronic Services & Trading, Evercommerce, Torrid Holdings, and the Glimpse Group will also make their debuts.

Other symbols: DNUTCURVEVCMHEPSVRAR
1 year ago - Barrons

Acumen Pharmaceuticals shares soar 25% in trading debut

Acumen Pharmaceuticals Inc. shares soared 25% in their trading debut Thursday, after the biotech's initial public offering priced at the high end of its proposed range. Acumen sold 10 million shares at ...

1 year ago - Market Watch

Acumen Pharmaceuticals Announces Pricing of Upsized Initial Public Offering

CHARLOTTESVILLE, Va., June 30, 2021 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (“Acumen” or “Acumen Pharmaceuticals”) (Nasdaq: ABOS), a clinical-stage biopharmaceutical company developing a novel ...

1 year ago - GlobeNewsWire